OBJECTIVE: To compare the clinical outcomes between letrozole and clomiphene citrate (CC) in gonadotropin-combined intrauterine insemination (IUI) cycles. DESIGN: Prospective pilot study. SETTING: One university hospital and two private infertility clinics. PATIENT(S): Ninety-three infertile couples eligible for superovulation and IUI. INTERVENTION(S): A letrozole dose of 2.5 mg/day (n = 66) or a CC dose of 100 mg/day (n = 27) was given on day 3-7 of the menstrual cycle, combined with human menopausal gonadotropin (hMG) at a dose 150 IU every other day starting on day 5. MAIN OUTCOME MEASURE(S): The number of mature follicles, serum estradiol (E2) and progesterone (P) levels, endometrial thicknesses on the day of human chorionic gonadotropin (hCG), and clinical pregnancy rates. RESULT(S): The patients' clinical characteristics were comparable between the two groups. The number of mature follicles (3.2 +/- 1.7 vs. 5.6 +/- 2.4) and serum E2 levels on the day of hCG (231.0 +/- 179.8 vs. 1,371.7 +/- 750.5 pg/mL) were significantly lower in the letrozole group. No significant differences were found in endometrial thickness measured on the day of hCG or clinical pregnancy rates (18.2% vs. 25.9%). The rate of patients with serum P levels > 1.0 ng/mL on the day of hCG was significantly lower in the letrozole group (4.5% vs. 25.9%). CONCLUSION(S): Letrozole produced a comparable pregnancy rate vs. CC in gonadotropin-combined IUI cycles. Our results should be confirmed in larger populations with proper randomization.
OBJECTIVE: To compare the clinical outcomes between letrozole and clomiphene citrate (CC) in gonadotropin-combined intrauterine insemination (IUI) cycles. DESIGN: Prospective pilot study. SETTING: One university hospital and two private infertility clinics. PATIENT(S): Ninety-three infertile couples eligible for superovulation and IUI. INTERVENTION(S): A letrozole dose of 2.5 mg/day (n = 66) or a CC dose of 100 mg/day (n = 27) was given on day 3-7 of the menstrual cycle, combined with human menopausal gonadotropin (hMG) at a dose 150 IU every other day starting on day 5. MAIN OUTCOME MEASURE(S): The number of mature follicles, serum estradiol (E2) and progesterone (P) levels, endometrial thicknesses on the day of human chorionic gonadotropin (hCG), and clinical pregnancy rates. RESULT(S): The patients' clinical characteristics were comparable between the two groups. The number of mature follicles (3.2 +/- 1.7 vs. 5.6 +/- 2.4) and serum E2 levels on the day of hCG (231.0 +/- 179.8 vs. 1,371.7 +/- 750.5 pg/mL) were significantly lower in the letrozole group. No significant differences were found in endometrial thickness measured on the day of hCG or clinical pregnancy rates (18.2% vs. 25.9%). The rate of patients with serum P levels > 1.0 ng/mL on the day of hCG was significantly lower in the letrozole group (4.5% vs. 25.9%). CONCLUSION(S): Letrozole produced a comparable pregnancy rate vs. CC in gonadotropin-combined IUI cycles. Our results should be confirmed in larger populations with proper randomization.
Authors: Anne Cooley; Laura Matthews; Stanislav Zelivianski; Ashley Hardy; Jacqueline S Jeruss Journal: Hum Reprod Date: 2011-11-10 Impact factor: 6.918
Authors: Russell Frank; Naama Steiner; Maryam Al Shatti; Jacob Ruiter-Ligeti; Michael H Dahan Journal: Arch Gynecol Obstet Date: 2021-01-03 Impact factor: 2.344
Authors: Antonio Requena; Julio Herrero; José Landeras; Esperanza Navarro; José L Neyro; Cristina Salvador; Rosa Tur; Justo Callejo; Miguel A Checa; Magí Farré; Juan J Espinós; Francesc Fábregues; María Graña-Barcia Journal: Hum Reprod Update Date: 2008-09-23 Impact factor: 15.610